ONTARIO OSTEOPOROSIS STRATEGY Ontario Osteoporosis Strategy The Ontario Osteoporosis Strategy represents the vision and coordinated efforts of many groups, including the Ministry of Health and Long-Term Care (MOHLTC), Ontario Women’s […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

Media Release Osteoporosis Canada and the International Osteoporosis Foundation underline their shared goal of improving clinical outcomes and preventing recurrent fractures in patients who have sustained fractures due to osteoporosis. […]

Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada – Updated August 6, 2013 Calcitonin is a hormone found naturally in our bodies. A synthetic form […]

LONG TERM CARE Long Term Care Video Series Osteoporosis Canada, Ontario Osteoporosis Strategy, University of Waterloo and GERAS Centre for Aging Research are excited to announce the launch of four […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]